SlideShare a Scribd company logo
1 of 17
Download to read offline
 It is an agency of the united states department
of health and human services (DHHS)
 Its headquarter located at White Oak,
Maryland
 The agency also has 223 field offices and13
laboratories located throughout the 50 states of
USA.
 FDA started opening office in foreign countries
including China ,India , Costa Rica , Chile ,
Belgium and UK.
Responsible for regulating and supervising
the safety of foods, dietary supplement,
biologicals, medical products, vaccines,
blood products, medical devices, radiation
emitting devices, veterinary products and
cosmetics. FDA also ensure that these
products are honestly, accurately and
informatively represented to the public.
FDA to regulate above mentioned areas has following
organisational bifurcation for effective implementation.
6 PRODUCT CENTER:
CBER (Centre for biologics evaluation & research)
CDRH (Centre for devices & radiological health)
CDER (Centre for drug evaluation & research)
CFSAN (Centre for food safety & applied nutrition)
Centre for tobacco products
Centre for veterinary devices
ONE RESEARCH CENTRE:
NCTR (National centre for toxicological research)
2 OFFICES:
ORA (Office of regulatory affairs) AND OCI (Office of Criminal
Investigations)
Center for Biologics Evaluation and Research
(CBER)
946
Center for Drug Evaluation and Research (CDER) 2,889
Center for Devices and Radiological Health (CDRH) 1,203
Center for Food Safety and Applied Nutrition
(CFSAN)
877
Center for Tobacco Products (CTP) 194
Center for Veterinary Medicine (CVM) 436
National Center for Toxicological Research (NCTR) 217
Office of the Criminal Investigations (OCI) 859
Office of Regulatory Affairs (ORA) 3,895
Total 11,516
As of Oct. 1, 2009, FDA employs the following numbers
of people in its centers/offices:
o Food
o Drugs
o Medical devices
o Vaccines, blood and biologicals
o Animal and veterinary
o Cosmetics
o Radiation emitting products
THAT DOES NOT REGULATE:
o Advertising – Federal trade commission
o Alcoholic beverages – Treasury department’s Bureau of Alcohol,
Tobacco.
o Drugs abuse - Drug enforcement administration
o Health insurance – Health care financing administration
o Meat and poultry – Agriculture’s food safety and inspection service
o Restaurant and grocery stores – Local county health department
o Pesticides – FDA and environmental protection agency
 Protecting the public health by assuring that
food are safe , sanitary and properly labelled
 Veterinary drugs and vaccines, biological
product, medical devices which are intended
for human use are safe and effective
 Protect the public from electronic product
radiation
 Regulating tobacco products
 Assuring cosmetic products are safe
 Provide the accurate science based
information.
CDER evaluates safety and effectiveness of drug
In vitro-in vivo testing of new drug by the company
Check and submit investigation report
Company submit IND for FDAs review
Company sends data to CDER in NDA
CDER review the data and proposed labeling
If risk-benefit ratio is established, drug is approved
for sale
After launching the drug , the FDA monitors its
performance
MEDWATCH: It is the FDA safety information and adverse
event reporting program.
Its alert provide timely new safety information on human
drugs , medical device and other biologicals
Its alert contain actionable information that may impact
both treatment and diagnostic choices for health care
professional and patient.
RESOURCES -
Report a serious medical product problem online
Reporting unlawful sales of medical products
Current drug storage
Index to drug specific information
Identifying recalled product
Provide guidelines to drug safety terms
FDA maintains a public record of proposed regulations
Encourages public participation in the federal rule
making process by alloying consumers to view and
comment on proposed action
FDA considers these comments when it draws up a final
rule or regulations.
DRUG WITHDRAWL AND MARKET
WITHDRAWL:
When a product is removed from the market or a
correction is made to the product because it is either
defective or potentially harmful
Sometimes a company discovers a problem in their
products and recall that product on its own basis other
time company recalls a product after company raises
concerns over any issues related to the drug.
 In India FDA ensures that food and medical
product exported from India to the US are
safe and effective
 Engaging with Indian regulatory
authorities to ensure the timely exchange of
information regarding clinical trials of drug
which are marketed in US
 Increased FDA inspection frequency
 Co-ordinating and collaborating on product
quality and safety issues with other Indian
government agencies.
 In support of the
agency's mission
to promote and
protect the
public health,
FDA's Strategic
Plan focuses on
four strategic
goals:
14
 Goal 1: Strengthen FDA for Today
and Tomorrow
 Goal 2: Improve Patient and
Consumer Safety
 Goal 3: Increase Access to New
Medical and Food Products
 Goal 4: Improve the Quality and
Safety of Manufactured Products and
the Supply Chain
TGA – Therapeutic Goods Administration
 Responsible for the regulation of therapeutic
goods in Australia.
 Therapeutic goods Act 1989, implemented on
15 Feb 1991
 Products with therapeutic claim must be
entered in ARTG.
 ARTG is a computer database of information
about TG approved for supply in or exported
from Australia.
 TGA is unit of FDHA (federal department of
health & ageing.
Therapeutic goods
 Any goods represented or taken to be for
therapeutic use unless excluded/included
under section 7 of TGA 1989.
REGULATION OF THERAPEUTIC GOODS:
1. Premarket assessment – QSE evaluation
A. Higher risk level – AUSTR – QSE
B. Lower risk level – AUSTL – QS
2. Licensing of manufacturers – GMP
3. Post market vigilance – testing & monitoring

More Related Content

What's hot

overview of Japan pharmaceutical regulatory authority - PMDA
overview of Japan  pharmaceutical regulatory authority - PMDAoverview of Japan  pharmaceutical regulatory authority - PMDA
overview of Japan pharmaceutical regulatory authority - PMDANandhanan
 
Drug regulatory authority
Drug regulatory authority Drug regulatory authority
Drug regulatory authority Rahul Gawande
 
US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.Venugopal N
 
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...sandeep bansal
 
Therapeutic good administration
Therapeutic good administrationTherapeutic good administration
Therapeutic good administrationSagar Savale
 
Regulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRegulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRama Shukla
 
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRATHERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRAManikant Prasad Shah
 
Drug Regulatory Agencies.
 Drug Regulatory Agencies. Drug Regulatory Agencies.
Drug Regulatory Agencies.Priyanka Chakote
 
Regulation of herbal drugs in india
Regulation of herbal drugs in indiaRegulation of herbal drugs in india
Regulation of herbal drugs in indiaRicha Patel
 
FDA Guidelines for Drug Development & Approval
FDA Guidelines for Drug Development & ApprovalFDA Guidelines for Drug Development & Approval
FDA Guidelines for Drug Development & Approvalrahimbrave
 
International Regulatory agencies
International Regulatory agenciesInternational Regulatory agencies
International Regulatory agenciesBeena Maddi
 
Usa and canada ppt final ranju hod augst
Usa and canada ppt final ranju hod augstUsa and canada ppt final ranju hod augst
Usa and canada ppt final ranju hod augstRanjiniDM
 
Quality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaQuality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaS S N D Balakrishna Ch
 
2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.Audumbar Mali
 

What's hot (20)

overview of Japan pharmaceutical regulatory authority - PMDA
overview of Japan  pharmaceutical regulatory authority - PMDAoverview of Japan  pharmaceutical regulatory authority - PMDA
overview of Japan pharmaceutical regulatory authority - PMDA
 
Drug regulatory authority
Drug regulatory authority Drug regulatory authority
Drug regulatory authority
 
US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.US - FDA Regulatory Agency Overview.
US - FDA Regulatory Agency Overview.
 
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...regulatory requirnment and approval procedure for drugs and cosmetics, medica...
regulatory requirnment and approval procedure for drugs and cosmetics, medica...
 
Therapeutic good administration
Therapeutic good administrationTherapeutic good administration
Therapeutic good administration
 
Regulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical IndustryRegulatory affairs in Pharmaceutical Industry
Regulatory affairs in Pharmaceutical Industry
 
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRATHERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
THERAPEUTIC GOODS ADMINISTRATION (TGA) and MHRA
 
Drug Regulatory Agencies.
 Drug Regulatory Agencies. Drug Regulatory Agencies.
Drug Regulatory Agencies.
 
Regulation of herbal drugs in india
Regulation of herbal drugs in indiaRegulation of herbal drugs in india
Regulation of herbal drugs in india
 
FDA Guidelines for Drug Development & Approval
FDA Guidelines for Drug Development & ApprovalFDA Guidelines for Drug Development & Approval
FDA Guidelines for Drug Development & Approval
 
International Regulatory agencies
International Regulatory agenciesInternational Regulatory agencies
International Regulatory agencies
 
ICH AND ICH GUIDELINES
ICH AND ICH GUIDELINESICH AND ICH GUIDELINES
ICH AND ICH GUIDELINES
 
Regulatory bodies & CRO
Regulatory bodies & CRORegulatory bodies & CRO
Regulatory bodies & CRO
 
Overview of the FDA
Overview of the FDAOverview of the FDA
Overview of the FDA
 
ICH GUIDELINES
ICH GUIDELINESICH GUIDELINES
ICH GUIDELINES
 
USFDA Over View
USFDA  Over ViewUSFDA  Over View
USFDA Over View
 
Regulatory Affairs Profession
Regulatory Affairs ProfessionRegulatory Affairs Profession
Regulatory Affairs Profession
 
Usa and canada ppt final ranju hod augst
Usa and canada ppt final ranju hod augstUsa and canada ppt final ranju hod augst
Usa and canada ppt final ranju hod augst
 
Quality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in IndiaQuality, Safety and Legislation of Herbal Products in India
Quality, Safety and Legislation of Herbal Products in India
 
2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.2. unit II, chapter-2 regulatory authorities and agencies.
2. unit II, chapter-2 regulatory authorities and agencies.
 

Similar to US FDA

Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalPpt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalRajashri Survase Ojha
 
Pharmaceutical regulatory authorities and agencies
Pharmaceutical regulatory authorities and agenciesPharmaceutical regulatory authorities and agencies
Pharmaceutical regulatory authorities and agenciesChintamBaladattaSai
 
Lecture 3: QC and QA-International perspective of USA, WHO, ICH & India
Lecture 3: QC and QA-International perspective of USA, WHO, ICH & IndiaLecture 3: QC and QA-International perspective of USA, WHO, ICH & India
Lecture 3: QC and QA-International perspective of USA, WHO, ICH & IndiaSapan Shah
 
Quality assurance process final
Quality assurance process finalQuality assurance process final
Quality assurance process finalRahibikram Thapa
 
Quality assurance process final
Quality assurance process finalQuality assurance process final
Quality assurance process finalKshitiz Thapa
 
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014Sathish Vemula
 
regulatory approval process of drug, cosmetic and herbals in canada
regulatory approval process of drug, cosmetic and herbals  in canada regulatory approval process of drug, cosmetic and herbals  in canada
regulatory approval process of drug, cosmetic and herbals in canada Richa Patel
 
Fda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science IndustryFda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science Industrydmanalan
 
Regulatory authorities of copyright liasion
Regulatory authorities of copyright liasionRegulatory authorities of copyright liasion
Regulatory authorities of copyright liasionRAMZAHASHMI
 

Similar to US FDA (20)

Usfda swatee
Usfda swateeUsfda swatee
Usfda swatee
 
Madhu k s
Madhu k s Madhu k s
Madhu k s
 
Industry and fda laision &
Industry and fda laision &Industry and fda laision &
Industry and fda laision &
 
Agencies dhwani
Agencies dhwaniAgencies dhwani
Agencies dhwani
 
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalPpt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
 
Pharmaceutical regulatory authorities and agencies
Pharmaceutical regulatory authorities and agenciesPharmaceutical regulatory authorities and agencies
Pharmaceutical regulatory authorities and agencies
 
Usfda
UsfdaUsfda
Usfda
 
Lecture 3: QC and QA-International perspective of USA, WHO, ICH & India
Lecture 3: QC and QA-International perspective of USA, WHO, ICH & IndiaLecture 3: QC and QA-International perspective of USA, WHO, ICH & India
Lecture 3: QC and QA-International perspective of USA, WHO, ICH & India
 
Roshan (1)
Roshan (1)Roshan (1)
Roshan (1)
 
What is FDA?
What is FDA?What is FDA?
What is FDA?
 
Quality assurance process final
Quality assurance process finalQuality assurance process final
Quality assurance process final
 
Quality assurance process final
Quality assurance process finalQuality assurance process final
Quality assurance process final
 
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
Pharma Uptoday Monthly Magazine Volume 5, Issue Aug 2014
 
Usfda sana 1
Usfda sana 1Usfda sana 1
Usfda sana 1
 
regulatory approval process of drug, cosmetic and herbals in canada
regulatory approval process of drug, cosmetic and herbals  in canada regulatory approval process of drug, cosmetic and herbals  in canada
regulatory approval process of drug, cosmetic and herbals in canada
 
Usfda
Usfda Usfda
Usfda
 
Fda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science IndustryFda gmp compliance for the Life Science Industry
Fda gmp compliance for the Life Science Industry
 
2003
20032003
2003
 
Regulatory authorities of copyright liasion
Regulatory authorities of copyright liasionRegulatory authorities of copyright liasion
Regulatory authorities of copyright liasion
 
MHRA.pptx
MHRA.pptxMHRA.pptx
MHRA.pptx
 

More from Suvarta Maru

case study - Urinary tract infection with diabetes mellitus
case study - Urinary tract infection with  diabetes mellitus case study - Urinary tract infection with  diabetes mellitus
case study - Urinary tract infection with diabetes mellitus Suvarta Maru
 
WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )Suvarta Maru
 
Various approachesto drug discovery
Various approachesto drug discoveryVarious approachesto drug discovery
Various approachesto drug discoverySuvarta Maru
 
Schedules of drugs
Schedules of drugsSchedules of drugs
Schedules of drugsSuvarta Maru
 
Quinolone antibacterials
Quinolone antibacterialsQuinolone antibacterials
Quinolone antibacterialsSuvarta Maru
 
Protein binding of drug
Protein binding of drugProtein binding of drug
Protein binding of drugSuvarta Maru
 
Preclinical trials
Preclinical trialsPreclinical trials
Preclinical trialsSuvarta Maru
 
Poison AND treatment
Poison AND treatmentPoison AND treatment
Poison AND treatmentSuvarta Maru
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDYSuvarta Maru
 
Pharmacoeconomics STUDY
Pharmacoeconomics STUDYPharmacoeconomics STUDY
Pharmacoeconomics STUDYSuvarta Maru
 
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)Suvarta Maru
 
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)Suvarta Maru
 
Non linear kinetics
Non linear kineticsNon linear kinetics
Non linear kineticsSuvarta Maru
 

More from Suvarta Maru (20)

case study - Urinary tract infection with diabetes mellitus
case study - Urinary tract infection with  diabetes mellitus case study - Urinary tract infection with  diabetes mellitus
case study - Urinary tract infection with diabetes mellitus
 
WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )
 
Various approachesto drug discovery
Various approachesto drug discoveryVarious approachesto drug discovery
Various approachesto drug discovery
 
USFDA & WHO
USFDA & WHOUSFDA & WHO
USFDA & WHO
 
Toxicity slides
Toxicity slidesToxicity slides
Toxicity slides
 
TGA & MHRA
TGA & MHRATGA & MHRA
TGA & MHRA
 
Thermal analysis
Thermal analysisThermal analysis
Thermal analysis
 
Stroke study
Stroke studyStroke study
Stroke study
 
Schedules of drugs
Schedules of drugsSchedules of drugs
Schedules of drugs
 
Schedule m
Schedule  m Schedule  m
Schedule m
 
Quinolone antibacterials
Quinolone antibacterialsQuinolone antibacterials
Quinolone antibacterials
 
Protein binding of drug
Protein binding of drugProtein binding of drug
Protein binding of drug
 
Preclinical trials
Preclinical trialsPreclinical trials
Preclinical trials
 
Poison AND treatment
Poison AND treatmentPoison AND treatment
Poison AND treatment
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDY
 
Pharmacoeconomics STUDY
Pharmacoeconomics STUDYPharmacoeconomics STUDY
Pharmacoeconomics STUDY
 
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
 
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
 
Non linear kinetics
Non linear kineticsNon linear kinetics
Non linear kinetics
 
New drug approval
New drug approvalNew drug approval
New drug approval
 

Recently uploaded

On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxPooja Bhuva
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxAreebaZafar22
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsMebane Rash
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxEsquimalt MFRC
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...pradhanghanshyam7136
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Pooja Bhuva
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxPooja Bhuva
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSCeline George
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.MaryamAhmad92
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxannathomasp01
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Jisc
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - Englishneillewis46
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfDr Vijay Vishwakarma
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxCeline George
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17Celine George
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 

Recently uploaded (20)

On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 

US FDA

  • 1.
  • 2.  It is an agency of the united states department of health and human services (DHHS)  Its headquarter located at White Oak, Maryland  The agency also has 223 field offices and13 laboratories located throughout the 50 states of USA.  FDA started opening office in foreign countries including China ,India , Costa Rica , Chile , Belgium and UK.
  • 3. Responsible for regulating and supervising the safety of foods, dietary supplement, biologicals, medical products, vaccines, blood products, medical devices, radiation emitting devices, veterinary products and cosmetics. FDA also ensure that these products are honestly, accurately and informatively represented to the public.
  • 4. FDA to regulate above mentioned areas has following organisational bifurcation for effective implementation. 6 PRODUCT CENTER: CBER (Centre for biologics evaluation & research) CDRH (Centre for devices & radiological health) CDER (Centre for drug evaluation & research) CFSAN (Centre for food safety & applied nutrition) Centre for tobacco products Centre for veterinary devices ONE RESEARCH CENTRE: NCTR (National centre for toxicological research) 2 OFFICES: ORA (Office of regulatory affairs) AND OCI (Office of Criminal Investigations)
  • 5.
  • 6.
  • 7. Center for Biologics Evaluation and Research (CBER) 946 Center for Drug Evaluation and Research (CDER) 2,889 Center for Devices and Radiological Health (CDRH) 1,203 Center for Food Safety and Applied Nutrition (CFSAN) 877 Center for Tobacco Products (CTP) 194 Center for Veterinary Medicine (CVM) 436 National Center for Toxicological Research (NCTR) 217 Office of the Criminal Investigations (OCI) 859 Office of Regulatory Affairs (ORA) 3,895 Total 11,516 As of Oct. 1, 2009, FDA employs the following numbers of people in its centers/offices:
  • 8. o Food o Drugs o Medical devices o Vaccines, blood and biologicals o Animal and veterinary o Cosmetics o Radiation emitting products THAT DOES NOT REGULATE: o Advertising – Federal trade commission o Alcoholic beverages – Treasury department’s Bureau of Alcohol, Tobacco. o Drugs abuse - Drug enforcement administration o Health insurance – Health care financing administration o Meat and poultry – Agriculture’s food safety and inspection service o Restaurant and grocery stores – Local county health department o Pesticides – FDA and environmental protection agency
  • 9.  Protecting the public health by assuring that food are safe , sanitary and properly labelled  Veterinary drugs and vaccines, biological product, medical devices which are intended for human use are safe and effective  Protect the public from electronic product radiation  Regulating tobacco products  Assuring cosmetic products are safe  Provide the accurate science based information.
  • 10. CDER evaluates safety and effectiveness of drug In vitro-in vivo testing of new drug by the company Check and submit investigation report Company submit IND for FDAs review Company sends data to CDER in NDA CDER review the data and proposed labeling If risk-benefit ratio is established, drug is approved for sale After launching the drug , the FDA monitors its performance
  • 11. MEDWATCH: It is the FDA safety information and adverse event reporting program. Its alert provide timely new safety information on human drugs , medical device and other biologicals Its alert contain actionable information that may impact both treatment and diagnostic choices for health care professional and patient. RESOURCES - Report a serious medical product problem online Reporting unlawful sales of medical products Current drug storage Index to drug specific information Identifying recalled product Provide guidelines to drug safety terms
  • 12. FDA maintains a public record of proposed regulations Encourages public participation in the federal rule making process by alloying consumers to view and comment on proposed action FDA considers these comments when it draws up a final rule or regulations. DRUG WITHDRAWL AND MARKET WITHDRAWL: When a product is removed from the market or a correction is made to the product because it is either defective or potentially harmful Sometimes a company discovers a problem in their products and recall that product on its own basis other time company recalls a product after company raises concerns over any issues related to the drug.
  • 13.  In India FDA ensures that food and medical product exported from India to the US are safe and effective  Engaging with Indian regulatory authorities to ensure the timely exchange of information regarding clinical trials of drug which are marketed in US  Increased FDA inspection frequency  Co-ordinating and collaborating on product quality and safety issues with other Indian government agencies.
  • 14.  In support of the agency's mission to promote and protect the public health, FDA's Strategic Plan focuses on four strategic goals: 14
  • 15.  Goal 1: Strengthen FDA for Today and Tomorrow  Goal 2: Improve Patient and Consumer Safety  Goal 3: Increase Access to New Medical and Food Products  Goal 4: Improve the Quality and Safety of Manufactured Products and the Supply Chain
  • 16. TGA – Therapeutic Goods Administration  Responsible for the regulation of therapeutic goods in Australia.  Therapeutic goods Act 1989, implemented on 15 Feb 1991  Products with therapeutic claim must be entered in ARTG.  ARTG is a computer database of information about TG approved for supply in or exported from Australia.  TGA is unit of FDHA (federal department of health & ageing.
  • 17. Therapeutic goods  Any goods represented or taken to be for therapeutic use unless excluded/included under section 7 of TGA 1989. REGULATION OF THERAPEUTIC GOODS: 1. Premarket assessment – QSE evaluation A. Higher risk level – AUSTR – QSE B. Lower risk level – AUSTL – QS 2. Licensing of manufacturers – GMP 3. Post market vigilance – testing & monitoring